Clinical trials: Asymptomatic Condition
Asymptomatic Cirrhosis, Clinically Significant Portal Hypertension
Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial
Decompensation of cirrhosis is a turning point in cirrhosis course, as associated with a marked decrease in life expectancy. Thus, prevention of decompensation is crucial.
- Trial name
- CARVECIR (NCT06263816)
- Testing
- Experimental group: Patients will be treated with carvedilol.
- Where
- 24 sites in France
- Volunteers
- 290 people
- Sponsor
- University Hospital, Tours